SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May, 2024

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                    Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                    No x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 

 

 

 

 

EXHIBITS

 

Exhibit
Number

  Description of Exhibits
     
99.1   Intimation dated May 6, 2024

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

   
Date: May 6, 2024 By: /s/ K Randhir Singh
    Name: K Randhir Singh
    Title: Company Secretary

 

3

 

Exhibit 99.1

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,

India.

CIN : L85195TG1984PLC004507

 

Tel       : +91 40 4900 2900

Fax      : +91 40 4900 2999

Email  : mail@drreddys.com

www.drreddys.com

 

May 6, 2024

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Ltd. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 

This is to inform that the Nomination, Governance and Compensation Committee of the Board of Directors of the Company at its meeting held on May 6, 2024, has approved the grant of stock options to the eligible employees under the Employees Stock Option Schemes of the Company:

 

Sl. No. Type of Option(s) Number of options granted Value Exercise Price per share ESOP Scheme
1

Indian Stock Options

*1,37,160 Fair Market Value Rs. 6,350/-

Dr. Reddy’s

Employees Stock

Option Scheme, 2018

#3,210
2

American Depository

Receipts (ADRs) Stock Options

*54,462 Fair Market Value Rs. 6,350/-

Dr. Reddy's

Employees

ADR Stock Option

Scheme, 2007 

 

*100% vesting at the end of 3 years. #Equally graded vesting in 3 years.

 

This is for your information and records.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

 

 

 

K. Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

 

 

 


Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 4 2024 まで 5 2024 Dr Reddys Laboratoriesのチャートをもっと見るにはこちらをクリック
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 5 2023 まで 5 2024 Dr Reddys Laboratoriesのチャートをもっと見るにはこちらをクリック